Class information for:
Level 1: FENOFIBRATE//FENOFIBRIC ACID//FIBRATES

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
10374 1069 37.4 66%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
171 3       MONASCUS//CITRININ//MONASCUS PURPUREUS 58457
419 2             STATINS//EZETIMIBE//SIMVASTATIN 16502
10374 1                   FENOFIBRATE//FENOFIBRIC ACID//FIBRATES 1069

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 FENOFIBRATE authKW 1186816 17% 23% 182
2 FENOFIBRIC ACID authKW 687385 4% 63% 38
3 FIBRATES authKW 603247 11% 17% 121
4 BEZAFIBRATE authKW 230825 5% 16% 49
5 INTERNAL MED CLIN PHARMACOL address 134149 3% 16% 29
6 MIXED DYSLIPIDEMIA authKW 127991 1% 41% 11
7 CIPROFIBRATE authKW 124202 2% 23% 19
8 MICRONIZED FENOFIBRATE authKW 93473 1% 55% 6
9 FIBRATE THERAPY authKW 85689 0% 100% 3
10 ST NIKOLAUS STIFTSHOSP GMBH address 85689 0% 100% 3

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Cardiac & Cardiovascular System 5101 28% 0% 296
2 Pharmacology & Pharmacy 3246 33% 0% 355
3 Peripheral Vascular Diseases 2231 14% 0% 149
4 Medicine, General & Internal 953 15% 0% 161
5 Endocrinology & Metabolism 832 12% 0% 126
6 Medicine, Research & Experimental 342 8% 0% 83
7 Chemistry, Medicinal 88 3% 0% 37
8 Medical Laboratory Technology 60 1% 0% 16
9 Toxicology 21 2% 0% 23
10 Chemistry, Analytical 18 3% 0% 36

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 INTERNAL MED CLIN PHARMACOL 134149 3% 16% 29
2 ST NIKOLAUS STIFTSHOSP GMBH 85689 0% 100% 3
3 BEZAFIBRATE INFARCT PREVENT STUDY COORDINATING CT 59500 0% 42% 5
4 ISRAELI SOC PREVENT HEART ATTACKS 51411 0% 60% 3
5 ROND POINT NATION 32129 0% 38% 3
6 BIOMEDICUM CARDIOL 28563 0% 100% 1
7 BIOTR OULU 28563 0% 100% 1
8 CARDIOL CLIN TRIALS UNIT 28563 0% 100% 1
9 CARDIOL HEALTHY HEART PROGRAM 28563 0% 100% 1
10 CARDIOL SERV LIPID CLIN 28563 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 ATHEROSCLEROSIS 17613 8% 1% 81
2 ARTERY 6499 1% 2% 11
3 JOURNAL OF CLINICAL LIPIDOLOGY 6304 1% 2% 12
4 CARDIOVASCULAR DIABETOLOGY 5174 1% 1% 15
5 NOUVELLE PRESSE MEDICALE 4165 1% 1% 12
6 CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL 3691 2% 1% 25
7 AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS 3311 1% 2% 7
8 PHARMACOLOGICAL REPORTS 3102 1% 1% 14
9 CLINICAL LIPIDOLOGY 2680 1% 2% 6
10 PROGRESS IN DRUG METABOLISM 2595 0% 9% 1

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 FENOFIBRATE 1186816 17% 23% 182 Search FENOFIBRATE Search FENOFIBRATE
2 FENOFIBRIC ACID 687385 4% 63% 38 Search FENOFIBRIC+ACID Search FENOFIBRIC+ACID
3 FIBRATES 603247 11% 17% 121 Search FIBRATES Search FIBRATES
4 BEZAFIBRATE 230825 5% 16% 49 Search BEZAFIBRATE Search BEZAFIBRATE
5 MIXED DYSLIPIDEMIA 127991 1% 41% 11 Search MIXED+DYSLIPIDEMIA Search MIXED+DYSLIPIDEMIA
6 CIPROFIBRATE 124202 2% 23% 19 Search CIPROFIBRATE Search CIPROFIBRATE
7 MICRONIZED FENOFIBRATE 93473 1% 55% 6 Search MICRONIZED+FENOFIBRATE Search MICRONIZED+FENOFIBRATE
8 FIBRATE THERAPY 85689 0% 100% 3 Search FIBRATE+THERAPY Search FIBRATE+THERAPY
9 RESIDUAL CARDIOVASCULAR RISK 60478 1% 35% 6 Search RESIDUAL+CARDIOVASCULAR+RISK Search RESIDUAL+CARDIOVASCULAR+RISK
10 BEZAFIBRATE PHARMACOKINETICS 57126 0% 100% 2 Search BEZAFIBRATE+PHARMACOKINETICS Search BEZAFIBRATE+PHARMACOKINETICS

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 MCKEAGE, K , KEATING, GM , (2011) FENOFIBRATE A REVIEW OF ITS USE IN DYSLIPIDAEMIA.DRUGS. VOL. 71. ISSUE 14. P. 1917 -1946 78 55% 45
2 KEATING, GM , (2011) FENOFIBRATE A REVIEW OF ITS LIPID-MODIFYING EFFECTS IN DYSLIPIDEMIA AND ITS VASCULAR EFFECTS IN TYPE 2 DIABETES MELLITUS.AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. VOL. 11. ISSUE 4. P. 227-247 72 54% 24
3 KEATING, GM , CROOM, KF , (2007) FENOFIBRATE - A REVIEW OF ITS USE IN PRIMARY DYSLIPIDAEMIA, THE METABOLIC SYNDROME AND TYPE 2 DIABETES MELLITUS.DRUGS. VOL. 67. ISSUE 1. P. 121-153 70 50% 85
4 GUAY, DRP , (1999) MICRONIZED FENOFIBRATE: A NEW FIBRIC ACID HYPOLIPIDEMIC AGENT.ANNALS OF PHARMACOTHERAPY. VOL. 33. ISSUE 10. P. 1083-1103 78 60% 48
5 NAJIB, J , (2002) FENOFIBRATE IN THE TREATMENT OF DYSLIPIDEMIA: A REVIEW OF THE DATA AS THEY RELATE TO THE NEW SUPRABIOAVAILABLE TABLET FORMULATION.CLINICAL THERAPEUTICS. VOL. 24. ISSUE 12. P. 2022-2050 60 61% 48
6 TZIOMALOS, K , ATHYROS, VG , (2006) FENOFIBRATE: A NOVEL FORMULATION (TRIGLIDE (TM)) IN THE TREATMENT OF LIPID DISORDERS: A REVIEW.INTERNATIONAL JOURNAL OF NANOMEDICINE. VOL. 1. ISSUE 2. P. 129-147 88 36% 25
7 FILIPPATOS, T , MILIONIS, HJ , (2008) TREATMENT OF HYPERLIPIDAEMIA WITH FENOFIBRATE AND RELATED FIBRATES.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 17. ISSUE 10. P. 1599-1614 57 44% 30
8 BALFOUR, JA , MCTAVISH, D , HEEL, RC , (1990) FENOFIBRATE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN DYSLIPIDEMIA.DRUGS. VOL. 40. ISSUE 2. P. 260-290 60 70% 133
9 SAHEBKAR, A , WATTS, GF , (2014) ROLE OF SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR MODULATORS IN MANAGING CARDIOMETABOLIC DISEASE: TALE OF A ROLLER-COASTER.DIABETES OBESITY & METABOLISM. VOL. 16. ISSUE 9. P. 780 -792 47 43% 11
10 TSIMIHODIMOS, V , LIBEROPOULOS, E , ELISAF, M , (2009) PLEIOTROPIC EFFECTS OF FENOFIBRATE.CURRENT PHARMACEUTICAL DESIGN. VOL. 15. ISSUE 5. P. 517-528 72 32% 17

Classes with closest relation at Level 1


Rank Class id link
1 9257 PRAVASTATIN//HMG COA REDUCTASE INHIBITORS//MEVALONIC ACID
2 36322 5 HT2C AND 5 HT2A RECEPTORS//HALOSTEROL A//HALOSTEROL B
3 12751 NIACIN//LAROPIPRANT//GPR109A
4 413 STATINS//LOW DENSITY LIPOPROTEIN CHOLESTEROL//ATORVASTATIN
5 6887 SMALL DENSE LDL//FAMILIAL COMBINED HYPERLIPIDEMIA//GRADIENT GEL ELECTROPHORESIS
6 22615 PROBUCOL//AGI 1067//SUCCINOBUCOL
7 7494 STATINS//RHABDOMYOLYSIS//STATIN INTOLERANCE
8 3123 PPAR DELTA//PPAR BETA DELTA//PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR
9 27435 OLIVE OIL DIET//AGE OF MYOCARDIAL INFARCT//AQUOPORIN 7
10 13608 EZETIMIBE//NPC1L1//CHOLESTEROL ABSORPTION INHIBITOR

Go to start page